Company / Working Capital
Amylyx Pharmaceuticals, Inc. Working Capital History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$301.0M
FY2025
5-year range
$87.6M / $382.6M
FY2021-FY2025
Trend
+86.9%
vs FY2024
Sector context
#141 of 213
Health Care
What the data says
At $301M, Amylyx Pharmaceuticals, Inc.'s working capital ranks #141 of 213 in the Health Care sector. Declined from $383M to $301M over the past 2 years.
Based on SEC 10-K filings.
$301M in FY2025 with a 3-year CAGR of -3.6%.
Declined from $383M to $301M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -3.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#141 of 213 in Health CareTop 66% of 213This company $301.0M Sector average $934.6M
▼
-67.8% below sector average
Key checks
Key Insights
- 3-year CAGR of -3.6%, indicating a declining trend.
- In FY2025, working capital increased 86.9% year-over-year.
- Ranks #141 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $301.0M | +86.9% |
| FY2024 | $161.0M | -57.9% |
| FY2023 | $382.6M | +14.0% |
| FY2022 | $335.5M | +283.2% |
| FY2021 | $87.6M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026